| http://www.w3.org/ns/prov#value | - But the thing that gets me about ImClone is that the company is valued as though Erbitux has already been a smashing success, as if it has already received approval for other therapies currently in trial such as earlier-stage colorectal cancers and head and neck cancers, extending its on-label marketing reach.
|
